Mechanistic Population Pharmacokinetic Modeling of Extended‐Release Metformin in Obese South African Women Living with HIV on Dolutegravir

Regulatory limits on metformin co‐administered with dolutegravir (DTG) derive from healthy‐volunteer studies in which DTG increased metformin exposure by 79% through organic cation transporter 2 inhibition, prompting a 1,000 mg/day metformin dose restriction. Whether this applies to women with HIV and severe obesity, a clinically important and understudied population for metformin‐DTG coadministration, is unknown. In a secondary analysis of a reported cohort, we developed a population pharmacokinetic model of extended‐release (XR) metformin with a zero‐order‐release, first‐order‐absorption structure scaled by lean body mass (LBM). Estimated glomerular filtration rate and DTG exposure were evaluated as clearance covariates, including DTG as a time‐varying competitive inhibitor. We simulated steady‐state exposures across body mass index (BMI) 30–60 kg/m 2 at 1000–3000 mg once daily compared to a DTG‐free reference model. Fifteen women contributed evaluable profiles (mean BMI 45.6 kg/m 2 ). Apparent clearance was 70.2 L/h, approximately 40% higher than reported non‐obese values, and DTG exposure was approximately 54% lower than in volunteer studies. LBM dominated clearance and volume, while no DTG exposure‐dependent effect on metformin clearance was identifiable within the observed low DTG exposure range. Simulated exposures rose near‐proportionally with dose and minimally with BMI; the proportion exceeding the lactic acidosis‐associated maximum concentration of 5 mg/L was 4.4% at 2000 mg/day, 16.9% at 2500 mg/day and 37.9% at 3000 mg/day, whereas none exceeded the lactic acidosis‐associated average steady‐state concentration of 4 mg/L. Although an interaction at higher DTG exposures cannot be excluded, the low exposures observed suggest the 1,000 mg/day restriction may underdose this obese population, supporting investigation of doses up to 2000 mg/day as the maximum authorized daily dose for metformin XR.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2026-11-07
DOI
https://doi.org/10.1002/cpt.70565
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanistic Population Pharmacokinetic Modeling of Extended‐Release Metformin in Obese South African Women Living with HIV on Dolutegravir

Veshni Pillay-Fuentes Lorente, Rohan M. Benecke, Roland van Rensburg, Eric H. Decloedt
2 links
Clinical Pharmacology & Therapeutics
Pharmacogenetics and Drug Metabolism
article

Mechanistic Population Pharmacokinetic Modeling of Extended‐Release Metformin in Obese South African Women Living with HIV on Dolutegravir

Veshni Pillay-Fuentes Lorente, Rohan M. Benecke, Roland van Rensburg, Eric H. Decloedt
article en

Abstract

Regulatory limits on metformin co‐administered with dolutegravir (DTG) derive from healthy‐volunteer studies in which DTG increased metformin exposure by 79% through organic cation transporter 2 inhibition, prompting a 1,000 mg/day metformin dose restriction. Whether this applies to women with HIV and severe obesity, a clinically important and understudied population for metformin‐DTG coadministration, is unknown. In a secondary analysis of a reported cohort, we developed a population pharmacokinetic model of extended‐release (XR) metformin with a zero‐order‐release, first‐order‐absorption structure scaled by lean body mass (LBM). Estimated glomerular filtration rate and DTG exposure were evaluated as clearance covariates, including DTG as a time‐varying competitive inhibitor. We simulated steady‐state exposures across body mass index (BMI) 30–60 kg/m 2 at 1000–3000 mg once daily compared to a DTG‐free reference model. Fifteen women contributed evaluable profiles (mean BMI 45.6 kg/m 2 ). Apparent clearance was 70.2 L/h, approximately 40% higher than reported non‐obese values, and DTG exposure was approximately 54% lower than in volunteer studies. LBM dominated clearance and volume, while no DTG exposure‐dependent effect on metformin clearance was identifiable within the observed low DTG exposure range. Simulated exposures rose near‐proportionally with dose and minimally with BMI; the proportion exceeding the lactic acidosis‐associated maximum concentration of 5 mg/L was 4.4% at 2000 mg/day, 16.9% at 2500 mg/day and 37.9% at 3000 mg/day, whereas none exceeded the lactic acidosis‐associated average steady‐state concentration of 4 mg/L. Although an interaction at higher DTG exposures cannot be excluded, the low exposures observed suggest the 1,000 mg/day restriction may underdose this obese population, supporting investigation of doses up to 2000 mg/day as the maximum authorized daily dose for metformin XR.

Clinical Pharmacology & Therapeutics
Stellenbosch University (ZA)
South African Medical Research Council, Harry Crossley Foundation, National Institutes of Health, Division of Research Capacity Development, Fogarty International Center
Good health and well-being
Openalex Percentile: Top 16%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon